BLISS GVS PHARMA LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 119.4 INR | -7.55% |
|
+4.78% | -4.13% |
| Sales 2022 | 7.47B 89.64M | Sales 2023 | 7.52B 90.14M | Capitalization | 7.42B 89M |
|---|---|---|---|---|---|
| Net income 2022 | 150M 1.8M | Net income 2023 | 709M 8.5M | EV / Sales 2022 | 1.03 x |
| Net cash position 2022 | 256M 3.06M | Net Debt 2023 | 335M 4.02M | EV / Sales 2023 | 1.03 x |
| P/E ratio 2022 |
53.8
x | P/E ratio 2023 |
10.6
x | Employees | 763 |
| Yield 2022 |
0.65% | Yield 2023 |
0.7% | Free-Float | 34.66% |
More Fundamentals
* Assessed data
More news
| 1 day | -7.55% | ||
| 1 week | +4.78% | ||
| Current month | +6.04% | ||
| 1 month | +3.02% | ||
| 3 months | +5.47% | ||
| 6 months | +41.86% | ||
| Current year | -4.13% |
1 week
114.80
131.10
1 month
108.00131.10
Current year
100.55142.15
1 year
71.00148.95
3 years
66.25148.95
5 years
66.25224.00
10 years
39.50230.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 41 | 21-01-20 | |
Deepak Sawant
DFI | Director of Finance/CFO | 44 | 22-12-29 |
| Compliance Officer | - | 15-11-08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 81 | 11-07-31 | |
| Director/Board Member | 40 | 08-07-28 | |
| Director/Board Member | 39 | 06-07-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 119.4 | -7.55% | 100 526 |
| 24-05-02 | 129.2 | +4.45% | 187,485 |
| 24-04-30 | 123.7 | -0.60% | 55,802 |
| 24-04-29 | 124.4 | +1.51% | 53,714 |
| 24-04-26 | 122.6 | +5.01% | 68,933 |
Delayed Quote Bombay S.E., May 03, 2024 at 05:29 am EDT
More quotes
Bliss GVS Pharma Limited is engaged in developing, manufacturing, and marketing pharmaceutical formulations. The Companyâs product categories include pharma products and other healthcare products. Its pharma products include pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, soft gelatine capsules and syrups. The Companyâs other healthcare products include balm, nasal inhaler, solution, soap, vaginal wash, roll on, shampoo, powder, spray, and petroleum jelly. Its brands include ANOMEX, ANOMEX DS, CONLAX 5/10, G - ALFENAC 100, GACET 80/125/170/250/500/1G, GMETH - 50/100, GSUNATE - 50/100/200, GVCAM - 7.5/15, GV-SOFT 1/2/3/4 G, LOFNAC - 12.5/25/50/100, MEFINOL, MELANEZ, MENINA - 25/100, TYRIDOL, VIGOTAMIN, COMIT 50, BG - CLIND, VAGID CL, ECOZOLE, GVGYL 500, GYNANFORT, GVGYL N, KLOVINAL, LONART, LONART FORTE, LONART Dispersible, FINMOL, GACET-500, and DOXYCYCLINE.
Sector
Pharmaceuticals
Calendar
2024-07-24
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -4.13% | 162M | |
| +19.92% | 43.67B | |
| +20.67% | 22.51B | |
| +13.67% | 14.6B | |
| +14.32% | 13.74B | |
| +44.52% | 11.91B | |
| -8.37% | 7.04B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.21% | 5.42B |
- Stock Market
- Equities
- BLISSGVS Stock
